Pulse Biosciences (PLSE) versus Anika Therapeutics (ANIK) Financial Analysis

Pulse Biosciences (NASDAQ:PLSE) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Pulse Biosciences and Anika Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pulse Biosciences 0 0 0 0 N/A
Anika Therapeutics 0 1 2 0 2.67

Anika Therapeutics has a consensus price target of $41.00, suggesting a potential downside of 2.89%. Given Anika Therapeutics’ higher possible upside, analysts plainly believe Anika Therapeutics is more favorable than Pulse Biosciences.

Earnings and Valuation

This table compares Pulse Biosciences and Anika Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Pulse Biosciences N/A N/A -$25.56 million N/A N/A
Anika Therapeutics $113.42 million 5.43 $31.81 million $1.96 21.54

Anika Therapeutics has higher revenue and earnings than Pulse Biosciences.

Profitability

This table compares Pulse Biosciences and Anika Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pulse Biosciences N/A -79.09% -72.29%
Anika Therapeutics 16.94% 9.53% 8.85%

Volatility and Risk

Pulse Biosciences has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 2.04, suggesting that its share price is 104% more volatile than the S&P 500.

Institutional and Insider Ownership

9.8% of Pulse Biosciences shares are held by institutional investors. Comparatively, 94.8% of Anika Therapeutics shares are held by institutional investors. 39.3% of Pulse Biosciences shares are held by company insiders. Comparatively, 6.6% of Anika Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Anika Therapeutics beats Pulse Biosciences on 9 of the 10 factors compared between the two stocks.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc., a clinical-stage medical technology company, develops therapeutic tissue treatment platform based on its proprietary nano-pulse stimulation (NPS) technology. Its NPS is a non-thermal, precise, and focal drug-free tissue treatment technology that initiates cell death within treated tissue used in oncology, dermatology/aesthetics, minimally invasive, and veterinary applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is headquartered in Hayward, California.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. has a strategic collaboration with the Institute for Applied Life Sciences at the University of Massachusetts Amherst to develop a therapy for rheumatoid arthritis. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply